- Home
- SOL vs HLVX Comparison
SOL vs HLVX Comparison
Compare SOL & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- HLVX
- Stock Information
- Founded
- SOL 2005
- HLVX 2020
- Country
- SOL United States
- HLVX United States
- Employees
- SOL N/A
- HLVX N/A
- Industry
- SOL Semiconductors
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- HLVX Health Care
- Exchange
- SOL Nasdaq
- HLVX Nasdaq
- Market Cap
- SOL 84.6M
- HLVX 83.7M
- IPO Year
- SOL 2008
- HLVX 2022
- Fundamental
- Price
- SOL $1.72
- HLVX $1.90
- Analyst Decision
- SOL Buy
- HLVX Hold
- Analyst Count
- SOL 3
- HLVX 5
- Target Price
- SOL $3.50
- HLVX $2.33
- AVG Volume (30 Days)
- SOL 148.5K
- HLVX 219.8K
- Earning Date
- SOL 05-14-2025
- HLVX 05-08-2025
- Dividend Yield
- SOL N/A
- HLVX N/A
- EPS Growth
- SOL N/A
- HLVX N/A
- EPS
- SOL N/A
- HLVX N/A
- Revenue
- SOL $85,621,000.00
- HLVX N/A
- Revenue This Year
- SOL N/A
- HLVX N/A
- Revenue Next Year
- SOL $45.37
- HLVX N/A
- P/E Ratio
- SOL N/A
- HLVX N/A
- Revenue Growth
- SOL N/A
- HLVX N/A
- 52 Week Low
- SOL $1.04
- HLVX $1.34
- 52 Week High
- SOL $3.00
- HLVX $15.60
- Technical
- Relative Strength Index (RSI)
- SOL 60.33
- HLVX 51.02
- Support Level
- SOL $1.63
- HLVX $1.82
- Resistance Level
- SOL $1.87
- HLVX $1.89
- Average True Range (ATR)
- SOL 0.11
- HLVX 0.07
- MACD
- SOL 0.02
- HLVX -0.02
- Stochastic Oscillator
- SOL 67.77
- HLVX 22.73
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.